Gemcitabine-induced radiation recall (GIRR) is a phenomenon wherein the administration of gemcitabine induces an inflammatory reaction within an area of prior radiation. We present the case of a 39-year-old female patient with metastatic breast cancer who experienced GIRR myositis 3 months following postoperative radiotherapy, with additional potential paraspinal myositis following ablative radiotherapy to the thoracic spine. A review of previously published cases of GIRR myositis was performed. The case and literature review describe the clinical course and presentation of GIRR, and highlight the importance of including radiation recall as part of a differential diagnosis when a patient undergoing chemotherapy experiences an inflammatory reaction at a prior site of radiation.
Introduction
Radiation recall describes a well-known, but poorly understood phenomenon by which administration of chemotherapy or another systemic agent induces an inflammatory reaction within a previously irradiated field [1] . Radiation recall was first described in 1959, when it was found that latent effects of radiation, such as dermatitis, could be induced by actinomycin D [2] . Though clinically rare, since that time radiation recall has been observed for various other systemic agents and inciting factors [3] . While the recall phenomenon is most commonly reported as dermatitis, it has also been observed in other organs including the lung, intestine, and muscles [1, [4] [5] [6] . Gemcitabine has previously been implicated in radiation recall. When reported, it is noted to preferentially affect internal tissue and organs [7] . Herein we report a case of a 39-year-old woman with myositis that is clinically consistent with gemcitabine-induced radiation recall (GIRR) myositis. We also review reported cases of GIRR myositis and discuss the findings and implications.
Case Description
Events are outlined in the timeline ( Fig. 1 ) and summarized below. In 2008, the 39-yearold patient was diagnosed with metastatic ER-negative, PR-negative, HER2-positive cancer. At initial presentation, PET scan demonstrated both regional lymph node involvement and osseous metastases. She was started on systemic therapy with Adriamycin and Cytoxan, followed by Taxol and Herceptin. Subsequent therapies included maintenance single-agent Herceptin, followed by Herceptin and lapatinib. By late 2011, her osseous disease showed complete radiologic response on PET scan, and she was offered local therapy to the primary tumor. In January 2012, she underwent a right mastectomy, with ypT2N1a disease, followed by postmastectomy radiation up to 50 Gy with a 10-Gy chest wall boost.
In late August 2012, she presented with a painful osseous lesion at the T12 vertebra and an impending pathologic fracture of the left distal femur. She underwent surgical stabilization of the femur with rod placement, followed by postoperative radiotherapy, 30 Gy in 10 fractions ( Fig. 2a ). T12 was treated with single-fraction stereotactic body radiotherapy (SBRT) up to 24 Gy.
In December 2012, gemcitabine (1,000 mg/m 2 , days 1 and 8) and Herceptin were given in a 21-day cycle. In January 2013, she presented to the Emergency Department with leg swelling, shortness of breath, and pleuritic chest pain to the lower thorax. Physical examination noted left leg swelling and some mild effusion of the left knee. The ultrasound was negative for deep vein thrombosis (DVT), and the chest CT was negative for pulmonary embolism. Symptoms were attributed to a viral syndrome with associated pleurisy.
The patient's symptoms had worsened at the time of her reexamination by oncology on March 2013. PET scan showed increased FDG activity and edema in the left thigh that was thought to be consistent with postradiation inflammatory changes ( Fig. 2b) . MRI of the thoracic spine demonstrated paraspinal muscle fluid collections and a new T12 fracture, and chemotherapy was held. CT-guided biopsy of the paraspinal fluid collection was negative for abscess or malignancy. Although a T12 vertebroplasty improved the chest/back pain and her swelling, her leg pain persisted.
On March 19, 2013 , gemcitabine and Herceptin were resumed with a 20% gemcitabine dose reduction. Within 2 days, she developed worsening leg pain and swelling, and required the use of a cane for ambulation. Repeat extremity ultrasound showed no evidence of DVT, but revealed marked, diffuse enlargement of the vastus medialis or rectus femoris muscles of the left thigh, suggestive of myositis. At that time, her providers noted that her symptoms appeared and worsened following each gemcitabine administration, but improved off chemotherapy. Given the temporal relationship and other negative evaluation, the patient's symptoms were attributed to GIRR from the prior palliative radiotherapy to the left femur. Gemcitabine was stopped, and she was started on dexamethasone and physical therapy. The patient required dexamethasone for relief of her symptoms until August 2013. After a slow taper, she regained leg function and was not rechallenged with gemcitabine.
Over the subsequent 3 years, she had received treatment with Herceptin, ado-trastuzumab, and eribulin/Herceptin without recurrence of the symptoms. Gait was described as normal at the most recent follow-up, and she was described as physically active, engaging in regular exercise. In retrospect, it is also possible that the exacerbation of pain and fluid collection within the paraspinal muscles of T12 seen in March of 2013 may have been related to recall myositis in that region.
Literature Review
A literature search was performed using the search terms "gemcitabine," "radiation," "recall," and "myositis" to compile known reports of GIRR myositis ( Table 1, Table 2 , Table 3 ). Twenty-one cases were identified as having myositis in a radiation port following gemcitabine treatment. Fractionated radiation doses ranged from 28 to 70.2 Gy.
The time interval between radiation and chemotherapy initiation ranged from 0 days to 4 months. The majority had chemotherapy more than 1 month after radiotherapy. The time between radiation and onset of recall symptoms varied from 4 weeks to 5.5 months. Only 1 patient had symptoms less than 1 month after radiation, 20 were ≥3 months, 10 were ≥4 months, and 7 were ≥5 months. All patients achieved at least partial improvement of their symptoms with discontinuation of gemcitabine, regardless of whether their treatment consisted of steroids (9 patients), NSAIDs (5 patients), analgesics (4 patients), or no treatment at all (2 patients). Out of the 9 confirmed patients who resumed chemotherapy following myositis, 5 patients underwent gemcitabine rechallenge, with only 1 patient requiring concomitant steroids for symptom control.
The patient described in the present report is consistent with other reported cases. The time intervals between chemotherapy, radiotherapy, and the onset of symptoms are within the range of the other cases. The current case of possible myositis at T12 was the only case associated with a single fraction of ablative radiotherapy. Interestingly, our patient had prior chest wall radiotherapy, but did not develop evidence of recall in that location. In review of the literature, this is consistent with other cases in which recall myositis did not appear in all prior sites of radiotherapy. Remote courses were less often affected by recall myositis. These findings are also consistent with prior reviews of radiation recall that suggest a possible relationship between the time interval from radiation to chemotherapy and the severity of recall symptoms [1, 3, 8] . However, such a correlation likely depends on the rela-tionship between several factors, such as drug type, dosage, radiation location, radiation dosage, and timing of each treatment [3] .
Discussion
Radiation recall is a delayed inflammatory response at a site of prior radiation [9, 10] . GIRR has been noted to have a predilection for soft tissue and internal organs, resulting in a less typical appearance of radiation recall. For example, GIRR has been documented to cause pseudocellulitis, acute ascending colitis, abdominal wall and subcutaneous fat stranding, optic neuritis, lymphangitis, rectal hemorrhage, brainstem radionecrosis, and myositis [5, 9, [11] [12] [13] . These atypical presentations highlight the importance of clinical awareness of GIRR.
The diagnosis of GIRR myositis is challenging, as it may appear similar to infection, thrombosis, or other sources of inflammation [14] . A few key signs may help distinguish this condition. Primarily, the inflammation is confined to a prior radiation portal. Furthermore, there is a temporal relationship between the timing of gemcitabine administration and appearance of symptoms [9] . Radiologic studies may be used to support the diagnosis of myositis with appearance of swelling and edema of the underlying musculature. They may also assist in ruling out other potential etiologies [15] . Because reported cases of myositis have been associated with elevated creatinine kinase and even compartment syndrome, appropriate recognition and treatment is essential to facilitate recovery and minimize morbidity [10, 16, 17] . Review of cases suggests that the most important factor for resolution is the discontinuation of gemcitabine, with the potential use of anti-inflammatory medications.
The mechanisms of action of radiation recall remain poorly understood. However, the varied presentations of GIRR, even within an individual's prior sites of radiotherapy, suggest that multiple factors influence both the appearance and severity of recall. Jeter et al. [11] proposed that the doses of gemcitabine of 600 mg/m 2 or higher may pose a higher recall risk. Others suggest that higher radiation treatment doses or shorter intervals between radiotherapy and chemotherapy may influence recall development [9] . However, these are not well-defined risk factors. With an increased use of gemcitabine across many tumor types, along with routine use of definitive and palliative radiotherapy, clinicians should be alerted to this possible complication.
We suspect that the exacerbation of pain at the site of T12 SBRT along with the MRI and biopsy findings are consistent with a focal recall myositis at that location. Our patient did not have further exacerbation of pain at that site with the dose-reduced gemcitabine. This suggests that the intervention with vertebroplasty may have affected the local environment. The underlying recall mechanism may also have differed from that in the leg. Radiation recall at an SBRT-treated site had been reported in the past, although the recall effect was induced by sorafenib and manifested itself in the form of dermatitis [18] .
Due to its rare and unpredictable onset, radiation recall continues to be a poorly understood phenomenon. This is further complicated by the possibility that there are multiple mechanisms for different medications (gemcitabine, carboplatin, etc.) and/or types of recall (dermatitis, myositis, etc.). Current hypotheses for explaining radiation recall include sensitivity of descendants of cells that survive radiation, changes in local vasculature, and drug-induced hypersensitivity reactions [1] . There is not enough evidence to support any definite mechanism [1, 9] . However, the drug-induced hypersensitivity hypothesis appears to best explain the characteristics of radiation recall. This hypothesis describes radiation recall as a nonimmune inflammatory reaction triggered by certain drugs at a site where the inflammatory threshold has been lowered by radiation. Prior radiation to a specific site may induce constant low-level expression of several inflammatory cytokines, including IL-1, IL-6, PGDFβ, TNF-α, and TGF-β [18] . Introduction of drugs such as gemcitabine may then lead to upregulation of such inflammatory cytokines inducing the recall reaction [1] . This theory is further supported by the various clinical presentations of radiation recall, including the timing of onset, the lack of worsening reactions following rechallenge in some cases, and the induction of recall from noncytotoxic agents (such as simvastatin) [1, 8] .
Conclusion
In conclusion, GIRR myositis is a rare, but significant reaction that may present like other conditions such as DVT or infection. As such, it should be part of the differential diagnosis when a patient on gemcitabine reports pain and swelling to a previously irradiated area, although other causes should be thoroughly investigated. In particular, GIRR myositis should be considered when there is a shorter time interval between the completion of radiation and the initiation of chemotherapy. Discontinuation of chemotherapy and possibly the use of anti-inflammatory medications are important steps to reduce symptoms and improve the patient's quality of life. In some cases, patients have been successfully rechallenged with gemcitabine, although that may not always be possible.
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